Sponsored Links
| Catalyst Pharmaceutical Partners And The National Institute On Drug Abuse Plan To Initiate U.S. Phase II(b) Clinical Trial For Cocaine Addiction |
 |
 |
 |
| Medical News - Alcohol and Addiction | |||
|
Catalyst Pharmaceutical Partners, Inc. (NasdaqCM: CPRX) announced that it has signed a non-binding Letter of Intent with the National Institute on Drug Abuse (NIDA) to conduct a U.S. Phase II(b) clinical trial evaluating CPP-109, Catalyst's formulation of vigabatrin, for the treatment of cocaine addiction... Read more: Alcohol / Addiction / Illegal Drugs News From Medical News Today
|